Finally, a recent study determined that the DPP-4 inhibitor teneligliptin increased (not significantly) the EPCs levels (CD34+) in T2DM patients after 28 weeks of treatment, although reduced SDF-1α levels, contrary to the tendency previously seen [190]. This evidence concerns the gene DPP4 and type 2 diabetes mellitus.